Immunotherapy Focused Consulting Company Provides Independent Support of the Value of Daily Body Restore® for Cancer Patients
SAN DIEGO, Aug. 1, 2018 /CNW/ -- Immune Advisors, LLC, a California-based company focused on forming, financing, and growing companies in the immunotherapy and regenerative medicine space, announced today publication of a manuscript entitled "Protection from chemotherapy- and antibiotic-mediated dysbiosis of the gut microbiota by a probiotic with digestive enzymes supplement." The paper was published in the peer-reviewed cancer focused journal, Oncotarget. Billionaire philanthropist, John Paul DeJoria, Co-Founder of Paul Mitchell Hair Care Products, stated: "As an investor in Daily Body Restore®, I am very proud of the results and the study speaks for itself."
This article was authored by Thomas Ichim, Ph.D. of Immune Advisors, LLC in collaboration with Dr. Santosh Kesari, MD Ph.D. of the Pacific Neuroscience Institute and the John Wayne Cancer Institute, and Kim Shafer of Daily Body Restore®, LLC, the developer of the supplement evaluated in the study.
The published results demonstrate that a commercially available supplement, Daily Body Restore (DBR)®, which combines nine strains of probiotics and ten digestive enzymes, provides benefits in counteracting the adverse effects of a chemotherapeutic agent, 5-fluorouracil (5-FU), and an antibiotic, vancomycin, on the gut microbiome. Using an in vitro model comprising bioreactors that simulate conditions in the various compartments of the intestinal tract, DBR® was added at in vivo doses and the composition and activity of gut bacteria was evaluated. "This study implemented a very powerful in vitro model of the intestinal microbiome in which to evaluate the effects of the probiotic with digestive enzymes supplement," stated Dr. Massimo Marzorati, founder of ProDigest, the Belgian Company who conducted the in vitro testing of gut dysbiosis used in the publication. "The supplement was able to improve the numbers and activity of the microbial communities that were adversely impacted by the chemotherapeutic agent and the antibiotic."
The article can be accessed at:
It is known that chemotherapy drugs that are routinely administered to cancer patients can negatively impact the microbiome, which, in turn, is believed to diminish the efficacy of immunotherapy based cancer treatments and causes adverse events such as gastrointestinal side effects1,2.
Thomas E. Ichim, Ph.D., first author of the publication, co-founder and managing partner of Immune Advisors, LLC commented, "In recent years, there has been a growing awareness in the medical and scientific communities that the composition of bacteria in the gut is intricately involved in shaping the immune system and drug responsiveness. The data recently published today, in my opinion, strongly support the viability of administering Daily Body Restore® to patients who are being treated with chemotherapy."
Contact: Thomas Ichim, Ph.D., Managing Partner, Immune Advisors, LLC, email@example.com, 858 353 0309
1 Routy et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97. http://science.sciencemag.org/content/359/6371/91.long
2 Alexander et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017 Jun 14(6):356-365. https://www.nature.com/articles/nrgastro.2017.20
SOURCE Immune Advisors, LLC